Race/ethnicity and lung cancer survival in the United States: a meta-analysis

Klugman, Madelyn; Xue, Xiaonan; Hosgood, H. Dean

doi:10.1007/s10552-019-01229-4

Cited by 24 publications

(19 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the relative frequency of major histocompatibility complex haplotypes varies widely between lung cancer patients of different ethnicities [8]. As well as influencing susceptibility to NSCLC, background genetic variation across populations may lead to differences in outcomes to treatment [9,10], tolerability [11,12] and metabolism of anticancer drugs [13][14][15]. Given these observations, it is questionable whether efficacy and safety data from clinical trials in NSCLC, which are often undertaken in individual countries or regions, can be extrapolated across different ethnicities.…”

mentioning

confidence: 99%

Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations

Kim

Melosky²,

Park

et al. 2021

Future Oncol.

View full text Add to dashboard Cite

Few data are available that have compared outcomes with different EGFR tyrosine kinase inhibitors (TKIs) specifically in Asian patients with EGFR mutation-positive non-small-cell lung cancer. In this narrative review, we have collated available data from prospective studies that have assessed first-, second- and third-generation EGFR TKIs in Asian populations, including subanalyses in individual countries (China and Japan). These data indicate that outcomes with first- and second-generation TKIs are broadly similar in Asian and non-Asian populations. However, while the third-generation EGFR TKI, osimertinib, confers significant overall survival benefit over erlotinib/gefitinib in non-Asians, this is not apparent in Asians, particularly in countries like Japan with well-resourced healthcare. Head-to-head comparisons of second- and third-generation EGFR TKIs, with OS as a primary end point, should be considered in Asia.

show abstract

mentioning

confidence: 99%

Egfr Tyrosine Kinase Inhibitors for EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Outcomes in Asian Populations

Kim

Melosky²,

Park

et al. 2021

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, emerging evidence suggests that Hispanics have a survival advantage in the context of a lung cancer diagnosis. For example, a recent meta-analysis reported relative survival advantages for Hispanic lung cancer patients compared with NHWs ( 10 ). Although this study was limited in scope, including only 5 studies based on breadth of search (eg, PubMed exclusively) and study-specific inclusion criteria, it supports the possibility of a Hispanic survival advantage in the context of lung cancer.…”

mentioning

confidence: 99%

Ethnic Differences in Survival Among Lung Cancer Patients: A Systematic Review

Price

Flores

Hamann

et al. 2021

JNCI Cancer Spectrum

View full text Add to dashboard Cite

Background Despite a substantially worse risk factor profile, Hispanics in the United States experience lower incidence of many diseases and longer survival than non-Hispanic Whites (NHWs), an epidemiological phenomenon known as the Hispanic Health Paradox (HHP). This systematic review evaluated the published longitudinal literature to address whether this pattern extends to lung cancer survival. Methods Searches of Medline, PubMed, Embase, Web of Science, and the Cochrane Library were conducted for January 1, 2000 to July 18, 2018. Records were restricted to articles written in English, employing a longitudinal design, and reporting a direct survival comparison (overall survival, OS; cancer-specific survival, CSS) between NHW and Hispanic lung cancer patients. Results A final sample of 29 full-text articles were included, including 28 fully adjusted models of OS and 21 of CSS. Overall, 26 (92.9%) OS models and 20 (95.2%) CSS models documented either no difference (16 OS, 11 CSS) or a Hispanic survival advantage (10 OS, 9 CSS). Both larger studies and those including foreign-born Hispanics were more likely to show a Hispanic survival advantage, while two studies of exclusively non-smokers showed a survival disadvantage. A number of reporting gaps were identified including Hispanic background and sociodemographic characteristics. Conclusions Hispanics exhibit similar or better survival in the context of lung cancer relative to NHWs despite a considerably worse risk factor profile. These findings support the HHP in the context of lung cancer. Further research is needed to understand the potential mechanisms of the HHP as it relates to lung cancer.

show abstract

“…Non-small cell lung cancer can be divided into squamous cell carcinoma, adenocarcinoma, and large cell lung cancer and other types. [ 25 ] LUAD is a primary epithelial tumor of the lung, which mostly originates from the bronchial mucosal epithelium or alveolar epithelium. In recent years, the incidence of LUAD has continued to rise and has now become the most common type of lung cancer worldwide.…”

Section: Discussionmentioning

confidence: 99%